Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

URN to cite this document:: urn:nbn:de:bvb:355-epub-573343
DOI to cite this document:: 10.5283/epub.57334

Weller, Johannes

; Schäfer, Niklas ; Schaub, Christina ; Potthoff, Anna-Laura ; Steinbach, Joachim P. ; Schlegel, Uwe ; Sabel, Michael

; Hau, Peter

; Seidel, Clemens ; Krex, Dietmar ; Goldbrunner, Roland ; Pietsch, Torsten ; Tzaridis, Theophilos ; Zeyen, Thomas ; Borger, Valeri ; Güresir, Erdem ; Vatter, Hartmut ; Herrlinger, Ulrich ; Schneider, Matthias

License: Creative Commons Attribution 4.0
PDF - Published Version
(708kB)

Date of publication of this fulltext: 29 Feb 2024 12:53

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Purpose The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to ...